GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioventix PLC (LSE:BVXP) » Definitions » Capital Expenditure

Bioventix (LSE:BVXP) Capital Expenditure : £-0.01 Mil (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Bioventix Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Bioventix's cash flow for capital expenditures for the six months ended in Dec. 2023 was £-0.01 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.01 Mil.

Bioventix Capital Expenditure Historical Data

The historical data trend for Bioventix's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioventix Capital Expenditure Chart

Bioventix Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.09 -0.34 -0.26 -0.01 -0.01

Bioventix Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.01 -0.01 - -0.01

Bioventix Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioventix (LSE:BVXP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioventix PLC (LSE:BVXP) » Definitions » Capital Expenditure
Comparable Companies
LSE:FARN LSE:OXB LSE:ARIX LSE:HVO LSE:SCLP LSE:FUM LSE:REDX LSE:OBD LSE:4BB LSE:ETX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
BVXP.GB:UK 51B:Germany
Address
East Street, 7 Romans Business Park, Farnham, Surrey, GBR, GU9 7SX
Website
http://www.bioventix.com
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others.

Bioventix (LSE:BVXP) Headlines

No Headlines